Table I.
Baseline clinical and laboratory characteristics of the 1,304 patients with COVID-19 infection.
| Variable | Patients (n=1,304) |
|---|---|
| Age (mean ± SD, years) | 64±17 |
| Sex, n (%) | |
| Male | 757(58) |
| Female | 547(42) |
| Co-morbidities, n (%) | |
| Diabetes mellitus | 245 (18.7) |
| Severe (class II) obesity (BMI ≥35 kg/m²) | 79(6) |
| Arterial hypertension | 422(32) |
| Gastrointestinal symptoms | 144(11) |
| AST (median, range, IU/l) | 33 (4-957) |
| ALT (median, range, IU/l) | 25 (3-993) |
| ALP (median, range, IU/l) | 65 (12-1335) |
| γ-GT (median, range, IU/l) | 35 (6-1304) |
| Total bilirubin (median, range, mg/dl) | 0.46 (0.11-33) |
| LDH (median, range, IU/l) | 324 (9-3552) |
| Albumin (median, range, g/dl) | 3.9 (1.8-5.4) |
| CRP (median, range, mg/l) | 55 (0.7-478) |
| INR (median, range) | 1.0 (0.7-11.3) |
| D-Dimers (median, range, mg/dl) | 0.9 (0.09-52) |
| Fibrinogen (median, range, mg/dl) | 536 (40-1074) |
| Ferritin (median, range, ng/ml) | 535 (10-2940) |
| WBC (median, range, x109/l) | 6.1 (1.2-45) |
| PLTs (mean ± SD, x109/l) | 211±94 |
AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; γ-GT, γ-glutamyl transpeptidase; LDH, lactate dehydrogenase; INR, international normalized ratio; CRP, C-reactive protein; WBC, white blood count; PLTs, platelets; BMI: body mass index.